J&J Teams Up With TB Foundation To Develop New Low-cost Treatment Aimed At Asia, Africa
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Johnson & Johnson plans to work with the Global Alliance for TB Drug Development to speed up the launch of what could be the first drug in decades with a new mechanism to treat tuberculosis
You may also be interested in...
J&J Worldwide Chairman Paul Stoffels On Precompetitive Alliances, Patent Pools And Tropical Drugs: An Interview With PharmAsia News
For Paul Stoffels, worldwide chairman, pharmaceuticals at Johnson & Johnson, innovation has been a long-time passion. Stoffels is regarded as a specialist in HIV therapies. In 1997, he left Janssen Research Foundation to become the CEO of Tibotec-Virco, which he transformed from a technology-based research company into an integrated R&D organization focused on the discovery and development of new drugs and diagnostics for HIV/AIDS and infectious diseases.
J&J Worldwide Chairman Paul Stoffels On Precompetitive Alliances, Patent Pools And Tropical Drugs: An Interview With PharmAsia News
For Paul Stoffels, worldwide chairman, pharmaceuticals at Johnson & Johnson, innovation has been a long-time passion. Stoffels is regarded as a specialist in HIV therapies. In 1997, he left Janssen Research Foundation to become the CEO of Tibotec-Virco, which he transformed from a technology-based research company into an integrated R&D organization focused on the discovery and development of new drugs and diagnostics for HIV/AIDS and infectious diseases.
Lifestyle Disease Trend Continues In Asia - WHO Epidemiology Report
HONG KONG - Growing economies, improved diets and access to healthcare are having a positive effect on health across Asia, but the incidence of infectious diseases remains stubbornly high and the impact is compounded by rises in non-communicable lifestyle diseases. The latest set of statistical data from the World Health Organization suggests more and more countries are forced to tackle both simultaneously, and global and local pharma companies are racing to fill unmet needs